Summary
This clinical trial, known as AALL1732, investigates whether adding the targeted drug inotuzumab ozogamicin (InO) to standard post-induction chemotherapy improves outcomes for patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study also tracks outcomes for patients with mixed phenotype acute leukemia (MPAL) and B-lymphoblastic lymphoma (B-LLy) who receive the same B-ALL chemotherapy without InO.
Description
The trial includes patients with:
High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL): This is the main focus of the study. Participants with this condition will be randomly assigned to different treatment groups to compare results.
Mixed Phenotype Acute Leukemia (MPAL): This is a rarer type of leukemia.
B-lymphoblastic Lymphoma (B-LLy): This is a type of lymphoma, a cancer of the lymphatic system.
What is being tested?
For high-risk B-ALL ----
Researchers are studying if adding a targeted drug, called inotuzumab ozogamicin, to standard chemotherapy improves treatment outcomes.
For MPAL and disseminated B-LLy ----
This study is the first to systematically track the outcomes of these patients when treated with the B-ALL chemotherapy regimen. They will not receive inotuzumab.
Principal Investigator
Study Coordinator
Research Contact
Lisa Luikart - lisa.luikart@vandaliahealth.org